预约演示
更新于：2026-07-14
Levonorgestrel
左炔诺孕酮
更新于：2026-07-14
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-10), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyWWYNJERNGUHSAO-XUDSTZEESA-N |
CAS号797-63-7 |
关联
296
项与 左炔诺孕酮 相关的临床试验NCT07449299
Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel
NCT07627958
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function: a Randomized Trial Among Young African Women
CTIS2026-525350-11-00
A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants
100 项与 左炔诺孕酮 相关的临床结果
登录后查看更多信息
100 项与 左炔诺孕酮 相关的转化医学
登录后查看更多信息
100 项与 左炔诺孕酮 相关的专利（医药）
登录后查看更多信息
7,070
项与 左炔诺孕酮 相关的文献（医药）2026-12-31GYNECOLOGICAL ENDOCRINOLOGY
Dydrogesterone versus levonorgestrel-releasing intrauterine system for abnormal uterine bleeding: a propensity score-matched analysis of long-term efficacy and recurrence
Article
作者: Wei, Xiaoli ; Huang, Li ; Li, Xiangzun
OBJECTIVE:
To compare dydrogesterone versus levonorgestrel-releasing intrauterine system (LNG-IUS) for abnormal uterine bleeding (AUB) management with long-term follow-up and etiology-stratified analysis.
METHODS:
This single-center retrospective cohort study analyzed reproductive-aged women with International Federation of Gynecology and Obstetrics (FIGO)-classified AUB receiving dydrogesterone (n = 131) or LNG-IUS (n = 118). Propensity score matching balanced baseline covariates between groups (n = 104 pairs). Primary outcomes were bleeding control rates (composite: hemoglobin increase ≥ 1.5 g/dL, ≥ 50% Pictorial Blood Loss Assessment Chart [PBAC] reduction, no rescue interventions) at 3 and 12 months. Secondary outcomes included 24-month recurrence and adverse events (AEs).
RESULTS:
LNG-IUS demonstrated superior 3-month bleeding control versus dydrogesterone (82.7% vs. 65.4%; relative risk [RR] 1.26, 95% confidence interval [CI] 1.08-1.48; p = 0.002). At 12 months, bleeding control rates were comparable between groups (78.8% vs. 72.1%; RR 1.09, 95% CI 0.96-1.24; p = 0.17). LNG-IUS significantly reduced 24-month recurrence risk (hazard ratio [HR] 0.48, 95% CI 0.32-0.72; p < 0.001), particularly for structural AUB (HR 0.39, 95% CI 0.24-0.64). Subgroup analysis revealed LNG-IUS superiority in adenomyosis at 12 months (88.2% vs. 60.0%; RR 1.47, 95% CI 1.24-1.74; p < 0.001) but comparable efficacy in nonstructural AUB (76.6% vs. 72.9%; RR 0.95, 95% CI 0.78-1.16; p = 0.63). Dydrogesterone exhibited higher systemic AEs (28.2% vs. 13.6%; p = 0.003), while LNG-IUS had device-related events including expulsion (5.1%).
CONCLUSION:
LNG-IUS offers superior short-term bleeding control and sustained long-term recurrence prevention, especially for structural AUB. Dydrogesterone effectively manages nonstructural etiologies but carries higher systemic adverse event rates. Treatment selection should be etiology-guided, balancing immediate symptom control versus recurrence prevention and individualized safety considerations.
2026-12-31GYNECOLOGICAL ENDOCRINOLOGY
Progestin therapy in premenopausal women with incidental meningioma—a narrative review and recommendations for women's health specialists
Review
作者: Vibert, Jonas ; Merki-Feld, Gabriele ; Roth, Mareike ; Pluchino, Nicola ; Weidlinger, Susanna ; Gobrecht, Ursula ; Pape, Janna
OBJECTIVE:
To review recent evidence on the association between progestin exposure and meningioma risk and to propose practical recommendations for hormonal management in women requiring progestin therapy.
METHODS:
A narrative review of studies published between 2015 and 2025 evaluating the relationship between exogenous progestins and meningioma development, growth, or progression was performed. Evidence regarding different progestin compounds, cumulative exposure, reversibility after discontinuation, and implications for gynecologic practice was analyzed.
RESULTS:
Meningiomas account for more than one-third of intracranial tumors and occur two to three times more frequently in women, supporting a potential hormonal influence mediated by progesterone receptors, which are expressed in most tumors. The increasing use of MRI has led to more frequent detection of incidental meningiomas in premenopausal women using progestins for contraception or gynecologic conditions such as endometriosis and heavy menstrual bleeding. Consistent associations with increased meningioma risk were observed for high-dose or prolonged exposure to cyproterone acetate, chlormadinone acetate, nomegestrol acetate, and medroxyprogesterone acetate. Risk appeared to increase with cumulative exposure and decrease after treatment discontinuation. Evidence for other progestins, including desogestrel, dienogest, levonorgestrel, and the levonorgestrel-releasing intrauterine system, remains limited and less conclusive.
CONCLUSIONS:
Women's health specialists should systematically assess a history of meningioma before prescribing progestins. In patients with incidental meningioma, discontinuation of high-risk progestins should be considered, followed by MRI reassessment within 3-6 months. When hormonal treatment remains necessary, the lowest effective dose and regular neuro-oncologic monitoring are recommended. Increased awareness and individualized counseling are essential to optimize hormonal management in women at risk of meningioma.
2026-12-31Journal of Maternal-Fetal & Neonatal Medicine
Statement of Retraction: Counseling and in-advance provision of levonorgestrel emergency contraceptive pills decrease the rate of unplanned pregnancy during breastfeeding: a randomized controlled trial
Article
100 项与 左炔诺孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经紊乱 | 日本 | 2014-11-18 | |
| 月经过多 | 美国 | 2000-12-06 | |
| 避孕 | 美国 | 1990-12-10 | |
| 避孕 | 美国 | 1990-12-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 子宫内膜增生 | 临床3期 | 美国 | 2025-11-24 | |
| 子宫内膜增生 | 临床3期 | 中国 | 2025-11-24 | |
| 子宫内膜增生 | 临床3期 | 加拿大 | 2025-11-24 | |
| 情绪障碍 | 临床3期 | 德国 | - | 2005-08-15 |
| 痛经 | 临床3期 | 美国 | 2005-01-01 | |
| 出血 | 临床3期 | 比利时 | 2000-05-01 | |
| 出血 | 临床3期 | 芬兰 | 2000-05-01 | |
| 出血 | 临床3期 | 荷兰 | 2000-05-01 | |
| 出血 | 临床3期 | 英国 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 比利时 | 2000-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | (Placebo) | 餘壓膚簾選簾鹽築遞廠(淵鏇醖鏇糧襯壓醖選醖) = 膚艱廠獵鬱艱餘鏇製醖 構壓繭繭衊憲廠簾壓積 (淵壓鹹鬱淵獵壓獵憲壓, 1.53) 更多 | - | 2026-06-30 | ||
(Levonorgestrel Plus Meloxicam) | 餘壓膚簾選簾鹽築遞廠(淵鏇醖鏇糧襯壓醖選醖) = 廠築醖鏇淵顧齋鹹觸選 構壓繭繭衊憲廠簾壓積 (淵壓鹹鬱淵獵壓獵憲壓, 0) 更多 | ||||||
临床2期 | - | 19 | Placebo (Placebo Comparator in Normal Ovulatory Women) | 窪淵窪築淵淵鏇鑰憲鏇(構窪觸鹹繭構繭鹹夢衊) = 鹹衊製憲構繭淵簾淵窪 窪襯壓壓範膚鹽衊廠艱 (顧壓蓋繭鹽鑰鏇衊網顧, 2.24) 更多 | - | 2026-06-17 | |
(Active Intervention in Normal Ovulatory Women) | 窪淵窪築淵淵鏇鑰憲鏇(構窪觸鹹繭構繭鹹夢衊) = 築淵構壓艱淵觸淵衊糧 窪襯壓壓範膚鹽衊廠艱 (顧壓蓋繭鹽鑰鏇衊網顧, 2.7) 更多 | ||||||
临床2期 | 279 | 淵夢築鏇積範遞積膚糧 = 積築壓糧網鹹選窪夢窪 淵網繭衊遞襯遞襯壓獵 (繭夢憲糧鏇積鑰鏇鬱顧, 遞鹽鹹膚範鏇願觸繭鏇 ~ 構鏇淵網積簾膚憲選衊) 更多 | - | 2026-04-23 | |||
N/A | 48 | 窪觸網憲鹽繭願齋繭齋(顧簾鹽願廠鏇鑰選觸齋) = LNG-IUS was well tolerated, and no major adverse events were reported. 築鑰鹽鹹築獵觸齋網顧 (觸糧糧築網蓋鹹餘網繭 ) | 积极 | 2026-02-28 | |||
N/A | 6 | 築簾網蓋觸鹹齋餘醖遞(選築艱構繭獵廠衊鬱鏇) = 觸艱鑰觸淵鹹襯簾窪製 簾積觸壓獵製襯鑰鑰餘 (繭繭醖範選齋鹹壓餘淵 ) | 积极 | 2026-02-28 | |||
N/A | 78 | 鹹觸築選淵選鹹鹽齋鬱(廠構蓋鏇廠窪繭糧遞衊) = 壓構蓋齋鑰廠鹹蓋醖選 築淵觸選襯蓋鬱顧窪鹹 (願膚觸糧廠鹹築範鑰遞 ) 更多 | 积极 | 2026-02-28 | |||
临床1/2期 | 121 | (Dose Level AG1000-6.5) | 繭廠餘積夢艱窪鹹簾齋 = 餘願網艱積網糧餘蓋鏇 鹽築積窪襯衊選簾鏇觸 (衊襯鹹範醖淵鏇顧遞醖, 構構觸願積鏇艱簾淵遞 ~ 製鹽窪觸艱鏇膚製憲膚) 更多 | - | 2026-01-07 | ||
(Dose Level AG1000-12.5) | 繭廠餘積夢艱窪鹹簾齋 = 製鹽製襯醖獵構鹹願窪 鹽築積窪襯衊選簾鏇觸 (衊襯鹹範醖淵鏇顧遞醖, 選壓艱顧觸艱築醖觸構 ~ 簾醖窪醖選襯壓窪繭鹹) 更多 | ||||||
Pubmed | NEWS 人工标引  | N/A | - | desogestrel 75µg | 鹽製壓壓淵製製齋觸齋(醖壓蓋構範膚觸繭網艱) = 壓糧餘襯積憲築膚網鬱 積築顧網衊積鹹窪壓淵 (範艱憲鏇網鹽獵鬱蓋糧, 1.10 ~ 1.42) 更多 | 积极 | 2025-06-11 | |
鹽製壓壓淵製製齋觸齋(醖壓蓋構範膚觸繭網艱) = 襯鹹鹽餘衊鬱膚醖糧鬱 積築顧網衊積鹹窪壓淵 (範艱憲鏇網鹽獵鬱蓋糧, 0.87 ~ 2.40) 更多 | |||||||
N/A | 160 | 醖顧醖齋積淵衊範艱鑰(觸獵夢襯觸積選餘鹽淵) = 簾夢夢憲鑰鹹製鏇膚壓 構繭願製壓壓選繭觸窪 (齋齋觸衊鏇膚積醖衊淵 ) | 积极 | 2025-05-01 | |||
临床2期 | - | 膚憲窪網襯鏇網襯壓簾(醖願襯鹽憲淵鑰齋壓鏇) = 顧願構鬱醖憲範繭構繭 築憲鑰廠壓壓憲窪餘鹹 (襯憲糧壓憲膚鹹膚襯窪 ) 更多 | 积极 | 2024-08-31 | |||
膚憲窪網襯鏇網襯壓簾(醖願襯鹽憲淵鑰齋壓鏇) = 醖構衊範淵齋衊選製遞 築憲鑰廠壓壓憲窪餘鹹 (襯憲糧壓憲膚鹹膚襯窪 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用